CN1813683A - 一种阿奇霉素的干混悬剂及其制备方法 - Google Patents
一种阿奇霉素的干混悬剂及其制备方法 Download PDFInfo
- Publication number
- CN1813683A CN1813683A CN 200510061861 CN200510061861A CN1813683A CN 1813683 A CN1813683 A CN 1813683A CN 200510061861 CN200510061861 CN 200510061861 CN 200510061861 A CN200510061861 A CN 200510061861A CN 1813683 A CN1813683 A CN 1813683A
- Authority
- CN
- China
- Prior art keywords
- azithromycin
- suspension
- preparation
- polymer binder
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 60
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 60
- 239000000725 suspension Substances 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 239000004925 Acrylic resin Substances 0.000 claims description 15
- 229920000178 Acrylic resin Polymers 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 229920005596 polymer binder Polymers 0.000 claims description 12
- 239000002491 polymer binding agent Substances 0.000 claims description 12
- 229920003149 Eudragit® E 100 Polymers 0.000 claims description 11
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 238000005469 granulation Methods 0.000 claims description 11
- 230000003179 granulation Effects 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- -1 hydroxypropyl Chemical group 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 235000009392 Vitis Nutrition 0.000 claims description 2
- 241000219095 Vitis Species 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 12
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 7
- 208000019505 Deglutition disease Diseases 0.000 description 7
- 235000019658 bitter taste Nutrition 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940003827 azithromycin 500 mg Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
成分 | 量(克) | 比例(%) |
阿奇霉素Eudragit E100(甲基丙烯酸丁酯∶甲基丙烯酸二甲氨基乙酯∶甲基丙烯酸甲酯(25∶50∶25)共聚物)羧甲基纤维素钠黄原胶磷酸钠二氧化硅蔗糖甘露醇草莓味香精乙醇制成1000袋 | 10040025251130700689204000毫升 | 5201.251.250.551.53534.451 |
成分 | 量(克) | 比例(%) |
阿奇霉素IV号丙烯酸树脂(甲基丙烯酸∶甲基丙烯酸甲酯(50∶50)共聚物羧甲基纤维素钠)黄原胶磷酸钠二氧化硅蔗糖甘露醇橙味香精乙醇制成1000袋 | 10040025251130700689204000毫升 | 5201.251.250.551.53534.451 |
时间min | 溶出度测定结果(%) | |
实施例1 | 实施例2 | |
2 | 50.82 | 51.05 |
5 | 93.21 | 92.19 |
10 | 100.99 | 100.33 |
15 | 100.41 | 100.12 |
30 | 98.30 | 96.46 |
45 | 99.77 | 97.05 |
50 | 98.48 | 98.82 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510061861 CN1813683B (zh) | 2005-12-07 | 2005-12-07 | 一种阿奇霉素的干混悬剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510061861 CN1813683B (zh) | 2005-12-07 | 2005-12-07 | 一种阿奇霉素的干混悬剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1813683A true CN1813683A (zh) | 2006-08-09 |
CN1813683B CN1813683B (zh) | 2011-08-31 |
Family
ID=36906119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510061861 Active CN1813683B (zh) | 2005-12-07 | 2005-12-07 | 一种阿奇霉素的干混悬剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1813683B (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100484530C (zh) * | 2007-08-14 | 2009-05-06 | 山东罗欣药业股份有限公司 | 一种阿奇霉素混悬颗粒及其制备方法 |
CN101966156A (zh) * | 2010-09-28 | 2011-02-09 | 石药集团欧意药业有限公司 | 一种阿奇霉素干混悬制剂及其制备方法 |
CN102657618A (zh) * | 2012-05-10 | 2012-09-12 | 四川百利药业有限责任公司 | 一种阿奇霉素颗粒及其制备方法 |
CN103610645A (zh) * | 2013-11-25 | 2014-03-05 | 浙江万马药业有限公司 | 一种非索非那定盐酸盐的药物组合物及制备方法 |
CN105012262A (zh) * | 2015-08-20 | 2015-11-04 | 广东安诺药业股份有限公司 | 掩盖苦味的阿奇霉素分散片及其制备方法 |
CN106619536A (zh) * | 2017-03-15 | 2017-05-10 | 深圳立健药业有限公司 | 一种头孢克肟干混悬颗粒的制备方法 |
CN107213118A (zh) * | 2017-05-26 | 2017-09-29 | 海南全星制药有限公司 | 一种阿奇霉素干混悬剂及其制备方法 |
CN107496353A (zh) * | 2017-10-10 | 2017-12-22 | 杭州市西溪医院 | 即溶型阿奇霉素口服混悬液的制备方法 |
CN108542887A (zh) * | 2018-05-23 | 2018-09-18 | 四川制药制剂有限公司 | 阿奇霉素干混悬剂的制备方法 |
CN110151704A (zh) * | 2019-07-05 | 2019-08-23 | 华裕(无锡)制药有限公司 | 阿奇霉素干混悬剂的制备方法 |
CN111450065A (zh) * | 2020-04-22 | 2020-07-28 | 南京嘉晨医药科技有限公司 | 一种阿奇霉素干混悬剂的制备方法 |
CN113332259A (zh) * | 2021-04-21 | 2021-09-03 | 海南普利制药股份有限公司 | 阿奇霉素干混悬剂 |
WO2022227116A1 (zh) * | 2021-04-25 | 2022-11-03 | 海南通用三洋药业有限公司 | 一种罗红霉素胶囊的制备方法 |
CN117368056A (zh) * | 2023-12-06 | 2024-01-09 | 山东则正医药技术有限公司 | 一种阿奇霉素药物粒径及粒度分布的测试方法 |
US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
-
2005
- 2005-12-07 CN CN 200510061861 patent/CN1813683B/zh active Active
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100484530C (zh) * | 2007-08-14 | 2009-05-06 | 山东罗欣药业股份有限公司 | 一种阿奇霉素混悬颗粒及其制备方法 |
CN101966156A (zh) * | 2010-09-28 | 2011-02-09 | 石药集团欧意药业有限公司 | 一种阿奇霉素干混悬制剂及其制备方法 |
CN101966156B (zh) * | 2010-09-28 | 2012-08-22 | 石药集团欧意药业有限公司 | 一种阿奇霉素干混悬制剂及其制备方法 |
CN102657618A (zh) * | 2012-05-10 | 2012-09-12 | 四川百利药业有限责任公司 | 一种阿奇霉素颗粒及其制备方法 |
CN103610645A (zh) * | 2013-11-25 | 2014-03-05 | 浙江万马药业有限公司 | 一种非索非那定盐酸盐的药物组合物及制备方法 |
CN105012262B (zh) * | 2015-08-20 | 2018-04-13 | 广东安诺药业股份有限公司 | 掩盖苦味的阿奇霉素分散片及其制备方法 |
CN105012262A (zh) * | 2015-08-20 | 2015-11-04 | 广东安诺药业股份有限公司 | 掩盖苦味的阿奇霉素分散片及其制备方法 |
CN106619536A (zh) * | 2017-03-15 | 2017-05-10 | 深圳立健药业有限公司 | 一种头孢克肟干混悬颗粒的制备方法 |
CN107213118A (zh) * | 2017-05-26 | 2017-09-29 | 海南全星制药有限公司 | 一种阿奇霉素干混悬剂及其制备方法 |
CN107213118B (zh) * | 2017-05-26 | 2018-03-27 | 海南全星制药有限公司 | 一种阿奇霉素干混悬剂及其制备方法 |
CN107496353A (zh) * | 2017-10-10 | 2017-12-22 | 杭州市西溪医院 | 即溶型阿奇霉素口服混悬液的制备方法 |
CN108542887A (zh) * | 2018-05-23 | 2018-09-18 | 四川制药制剂有限公司 | 阿奇霉素干混悬剂的制备方法 |
CN110151704A (zh) * | 2019-07-05 | 2019-08-23 | 华裕(无锡)制药有限公司 | 阿奇霉素干混悬剂的制备方法 |
CN111450065A (zh) * | 2020-04-22 | 2020-07-28 | 南京嘉晨医药科技有限公司 | 一种阿奇霉素干混悬剂的制备方法 |
CN111450065B (zh) * | 2020-04-22 | 2022-04-01 | 南京嘉晨医药科技有限公司 | 一种阿奇霉素干混悬剂的制备方法 |
US12031128B2 (en) | 2021-04-07 | 2024-07-09 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
CN113332259A (zh) * | 2021-04-21 | 2021-09-03 | 海南普利制药股份有限公司 | 阿奇霉素干混悬剂 |
WO2022227116A1 (zh) * | 2021-04-25 | 2022-11-03 | 海南通用三洋药业有限公司 | 一种罗红霉素胶囊的制备方法 |
CN117368056A (zh) * | 2023-12-06 | 2024-01-09 | 山东则正医药技术有限公司 | 一种阿奇霉素药物粒径及粒度分布的测试方法 |
CN117368056B (zh) * | 2023-12-06 | 2024-04-12 | 山东则正医药技术有限公司 | 一种阿奇霉素药物粒径及粒度分布的测试方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1813683B (zh) | 2011-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1813683B (zh) | 一种阿奇霉素的干混悬剂及其制备方法 | |
BRPI0211453B1 (pt) | Composição de esporos de bactérias não patogênicas do gênero bacillus adsorvidas em uma matriz e seu processo de obtenção | |
CN101088492B (zh) | 盐酸吉西他滨稳定的过饱和溶液及其制备方法 | |
CN113041231B (zh) | 一种替比培南酯细粒剂组合物及其制备方法 | |
CN102311452B (zh) | 头孢克肟晶体、其制备方法及含有该晶体的片剂组合物 | |
CN100496459C (zh) | 复方甘草药物制剂及其制备方法 | |
CN102210655A (zh) | 一种头孢匹胺钠微球及其制备方法 | |
CN101301280A (zh) | 一种适用于牲畜驱虫的缓释片产品 | |
CN101548979A (zh) | 一种治疗肠炎、菌痢的药物新组合 | |
CN1165313C (zh) | 克拉霉素缓释胶囊 | |
CN100484530C (zh) | 一种阿奇霉素混悬颗粒及其制备方法 | |
CN101081227B (zh) | 甘草酸二铵的组合物 | |
CN101513409B (zh) | 一种头孢氨苄的药物组合物 | |
CN1559503A (zh) | 芒果止咳胶囊和长效胶囊的制备方法 | |
CN103432087B (zh) | 一种注射用盐酸克林霉素制剂及其制备方法 | |
CN1772024A (zh) | 一种消炎癣湿膏剂及其制备方法 | |
CN103230372B (zh) | 注射用盐酸莫西沙星粉针及其制备方法 | |
CN104739881A (zh) | 一种高存活率的复方嗜酸乳杆菌颗粒制备方法 | |
CN106619523B (zh) | 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺颗粒及其制备方法 | |
CN101966156A (zh) | 一种阿奇霉素干混悬制剂及其制备方法 | |
CN113546160A (zh) | 一种药物组合物及其用途 | |
CN1365704A (zh) | 纳米小儿化食制剂药物及其制备方法 | |
CN1362243A (zh) | 纳米五福化毒制剂药物及其制备方法 | |
CN1530113A (zh) | 灯盏花素分散片组合物及其制备方法 | |
CN1371688A (zh) | Vc-磷酸酯镁在医药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN PULIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN MINHUA Effective date: 20120809 Owner name: ZHEJIANG POLY PHARMACEUTICAL CO., LTD. HANGZHOU SA Effective date: 20120809 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310009 HANGZHOU, ZHEJIANG PROVINCE TO: 571127 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120809 Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee after: Hainan Poly Pharm Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 310009, Lane 10, Shangcheng District, Zhejiang, Hangzhou Patentee before: Fan Minhua |
|
C56 | Change in the name or address of the patentee |
Owner name: HAINAN PLOY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HAINAN PULIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee before: Hainan Poly Pharm Co.,Ltd. Patentee before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhu Xulei Document name: Deemed not to have given notice |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230117 Address after: 571127 Guilin Ocean Economic Development Zone, Meilan District, Haikou City, Hainan Province Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Address before: 571127 Guilin Ocean Economic and Technological Development Zone, Meilan District, Haikou City, Hainan Province Patentee before: HAINAN POLY PHARM. Co.,Ltd. Patentee before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhu Xulei Document name: Notification of Conformity |